MARK CORRIGAN
CIK 1250661 · President & CEO · last filed 2025-12-10
MARK CORRIGAN is a President & CEO who has filed 60 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $217.3K of WVE on Dec 10, 2025. Across all open-market trades the lifetime net is −$9.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $132.3K across reported positions. 17 SEC filings were submitted jointly with SEPRACOR INC /DE/.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$132.3K
10
60
-$9.41M
Filer Profile
CAMBRIDGE, MA 02138-1002
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | Director | 28,815 | $4.59 | $132.3K | -$217.3K | 8 | 2025-12-10 |
| TREVENA INC (TRVN) Delisted | Director | — | $0.01 | — | $0 | 2 | 2024-06-14 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 288 | $1.42 | $409 | -$2.0K | 6 | 2022-08-04 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 3 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Director | — | — | — | $0 | 3 | 2017-03-01 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | 21,859 | — | — | $0 | 2 | 2015-06-08 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Director | 0 | — | — | -$400.0K | 2 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Director | 5,498 | — | — | -$1.17M | 9 | 2013-06-14 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | President & CEO | 87,205 | — | — | $0 | 3 | 2010-03-03 |
| SEPRACOR INC /DE/ (SEPR) Delisted | Executive VP, R&D | 70,668 | — | — | -$7.62M | 10 | 2009-10-19 |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-10 | WVE | Sell (S) | −16,115 | -$217.3K | EDGAR |
| 2025-12-08 | WVE | Notice (144) | −16,115 | -$120.7K | EDGAR |
| 2025-08-13 | WVE | Grant (A) | +12,700 | $0 | EDGAR |
| 2024-08-14 | WVE | Grant (A) | +32,230 | $0 | EDGAR |
| 2024-06-14 | TREVENA INC (TRVN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-08-09 | WVE | Grant (A) | — | $0 | EDGAR |
| 2023-07-20 | TREVENA INC (TRVN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-17 | WVE | Grant (A) | — | $0 | EDGAR |
| 2022-08-04 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −10,297 | -$2.0K | EDGAR |
| 2021-08-18 | WVE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.